[go: up one dir, main page]

MX2019009100A - Nuevos derivados de triazolo[4,5-d]pirimidina. - Google Patents

Nuevos derivados de triazolo[4,5-d]pirimidina.

Info

Publication number
MX2019009100A
MX2019009100A MX2019009100A MX2019009100A MX2019009100A MX 2019009100 A MX2019009100 A MX 2019009100A MX 2019009100 A MX2019009100 A MX 2019009100A MX 2019009100 A MX2019009100 A MX 2019009100A MX 2019009100 A MX2019009100 A MX 2019009100A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
novel triazolo
triazolo
novel
formula
Prior art date
Application number
MX2019009100A
Other languages
English (en)
Other versions
MX391724B (es
Inventor
Nettekoven Matthias
Rogers-Evans Mark
Grether Uwe
Kimbara Atsushi
Roever Stephan
Schmitt Sébastien
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019009100A publication Critical patent/MX2019009100A/es
Publication of MX391724B publication Critical patent/MX391724B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la formula (I): (Ver Fórmula) en la que de R1 a R4 tienen los significados definidos en la descripción y en las reivindicaciones. El compuesto de la fórmula (I) puede utilizarse como medicamento.
MX2019009100A 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina. MX391724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13183385 2013-09-06
PCT/EP2014/068640 WO2015032769A1 (en) 2013-09-06 2014-09-03 Novel triazolo[4,5-d]pyrimidine derivatives

Publications (2)

Publication Number Publication Date
MX2019009100A true MX2019009100A (es) 2019-09-16
MX391724B MX391724B (es) 2025-03-21

Family

ID=49111076

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009100A MX391724B (es) 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2016002117A MX367084B (es) 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016002117A MX367084B (es) 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina.

Country Status (31)

Country Link
US (1) US9593123B2 (es)
EP (3) EP3041843B1 (es)
JP (1) JP6441356B2 (es)
KR (3) KR20220140651A (es)
CN (1) CN105555788B (es)
AR (1) AR097553A1 (es)
AU (1) AU2014317229B2 (es)
CA (1) CA2915766C (es)
CL (1) CL2016000495A1 (es)
CR (1) CR20160076A (es)
DK (2) DK3483163T3 (es)
EA (1) EA028335B1 (es)
ES (2) ES2883923T3 (es)
HR (2) HRP20190361T1 (es)
HU (2) HUE055201T2 (es)
IL (1) IL243092B (es)
LT (2) LT3483163T (es)
MA (1) MA38826B1 (es)
MX (2) MX391724B (es)
MY (1) MY191628A (es)
PE (2) PE20160691A1 (es)
PH (1) PH12016500250B1 (es)
PL (2) PL3041843T3 (es)
PT (2) PT3041843T (es)
RS (2) RS62234B1 (es)
SG (1) SG11201601714UA (es)
SI (2) SI3483163T1 (es)
TR (1) TR201900662T4 (es)
TW (1) TWI705966B (es)
UA (1) UA116395C2 (es)
WO (1) WO2015032769A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162630A1 (en) * 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
EA031735B1 (ru) 2014-11-07 2019-02-28 Ф. Хоффманн-Ля Рош Аг ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107001405B (zh) * 2015-11-06 2019-03-05 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
KR20230062680A (ko) * 2016-06-23 2023-05-09 에프. 호프만-라 로슈 아게 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체
WO2017220544A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2017220516A1 (en) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2018015088A1 (en) 2016-06-23 2018-01-25 F. Hoffmann-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
CN106478639B (zh) * 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432247B (zh) * 2016-09-27 2018-06-29 郑州大学 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用
CN106432248B (zh) * 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN106928296A (zh) * 2017-02-06 2017-07-07 上海华升生物科技有限公司 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法
CN107033148B (zh) * 2017-05-03 2018-10-26 郑州大学 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用
CN106928235A (zh) * 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN109516990B (zh) * 2017-09-19 2021-06-01 天津药物研究院有限公司 嘧啶并三氮唑类化合物、其制备方法和用途
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用
CN119912457B (zh) * 2025-03-03 2025-10-10 郑州大学 嘧啶并三氮唑类化合物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814458A (pt) 1997-09-02 2001-10-23 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de disfunções afetivas
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2006009698A2 (en) * 2004-06-17 2006-01-26 The Regents Of The University Of California Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP2010526836A (ja) 2007-05-10 2010-08-05 ジーイー・ヘルスケア・リミテッド カンナビノイドCB2レセプターに対して活性を有するイミダゾール(1,2−a)ピリジン及び関連化合物
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US9469614B2 (en) 2011-10-27 2016-10-18 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
BR112014032996A2 (pt) 2012-07-04 2018-05-15 Hoffmann La Roche derivados de adamantil como agonistas do receptor de canabinoide 2
DK2928868T3 (en) 2012-12-07 2017-10-23 Hoffmann La Roche Pyridine-2-amides which can be used as CB2 agonists
HUE036911T2 (hu) 2012-12-07 2018-08-28 Hoffmann La Roche Új piridin származékok
ES2643056T3 (es) 2012-12-07 2017-11-21 F. Hoffmann-La Roche Ag Piridina-2-amidas útiles como agonistas de cb2
CN104837830B (zh) 2012-12-07 2018-07-20 霍夫曼-拉罗奇有限公司 作为cb2受体激动剂的吡嗪衍生物
PT2964646T (pt) 2013-03-07 2017-06-29 Hoffmann La Roche Novos derivados de pirazol
RS57461B1 (sr) 2013-05-02 2018-09-28 Hoffmann La Roche Derivati purina kao agonisti cb2 receptora
AU2014261546B2 (en) 2013-05-02 2018-01-18 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as CB2 receptor agonists
CN105283452B (zh) 2013-06-11 2019-01-04 豪夫迈·罗氏有限公司 四唑酮衍生物

Also Published As

Publication number Publication date
PT3041843T (pt) 2019-02-26
LT3041843T (lt) 2019-03-12
PT3483163T (pt) 2021-08-24
MA38826A1 (fr) 2016-05-31
CA2915766A1 (en) 2015-03-12
EP3041843B1 (en) 2019-01-02
HRP20211322T1 (hr) 2021-11-26
WO2015032769A1 (en) 2015-03-12
AU2014317229A1 (en) 2016-01-07
PE20160691A1 (es) 2016-07-28
DK3483163T3 (da) 2021-08-30
CA2915766C (en) 2023-09-26
EP3943497A1 (en) 2022-01-26
KR20210074404A (ko) 2021-06-21
RS58390B1 (sr) 2019-04-30
PL3483163T3 (pl) 2021-11-22
US20160168158A1 (en) 2016-06-16
MA38826B1 (fr) 2016-12-30
US9593123B2 (en) 2017-03-14
EP3483163A2 (en) 2019-05-15
AU2014317229B2 (en) 2018-11-08
EA201690478A1 (ru) 2016-06-30
NZ715085A (en) 2021-05-28
IL243092A0 (en) 2016-02-01
TWI705966B (zh) 2020-10-01
UA116395C2 (uk) 2018-03-12
IL243092B (en) 2019-06-30
CR20160076A (es) 2016-04-01
EA028335B1 (ru) 2017-11-30
TW201542551A (zh) 2015-11-16
PH12016500250A1 (en) 2016-05-16
NZ756513A (en) 2021-05-28
MX2016002117A (es) 2016-07-05
KR102349567B1 (ko) 2022-01-11
CN105555788B (zh) 2018-11-23
CN105555788A (zh) 2016-05-04
EP3483163B1 (en) 2021-06-23
HUE041760T2 (hu) 2019-05-28
AR097553A1 (es) 2016-03-23
DK3041843T3 (en) 2019-03-25
SG11201601714UA (en) 2016-04-28
MX391724B (es) 2025-03-21
HRP20190361T1 (hr) 2019-04-05
RS62234B1 (sr) 2021-09-30
KR102454344B1 (ko) 2022-10-14
HK1219277A1 (zh) 2017-03-31
KR20160050061A (ko) 2016-05-10
PL3041843T3 (pl) 2019-06-28
TR201900662T4 (tr) 2019-02-21
ES2883923T3 (es) 2021-12-09
SI3041843T1 (sl) 2019-04-30
JP2016532707A (ja) 2016-10-20
CL2016000495A1 (es) 2016-10-07
ES2714094T3 (es) 2019-05-27
MX367084B (es) 2019-08-05
PH12016500250B1 (en) 2019-09-13
PE20191528A1 (es) 2019-10-23
EP3041843A1 (en) 2016-07-13
EP3483163A3 (en) 2019-07-24
LT3483163T (lt) 2021-09-10
KR20220140651A (ko) 2022-10-18
SI3483163T1 (sl) 2021-11-30
MY191628A (en) 2022-07-04
JP6441356B2 (ja) 2018-12-19
HUE055201T2 (hu) 2021-11-29

Similar Documents

Publication Publication Date Title
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
CR20150250A (es) Nuevos derivados de piridina
ECSP13013074A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
CR20150447A (es) Nuevos derivados de pirazol
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20150440A (es) Nuevos derivados de piridina
GT201400142A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016004933A (es) Inhibidores de pirimidina del fgfr4.
CR20140464A (es) Compuestos de heterociclilo
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
UY35764A (es) El uso de picolinamidas macrociclicas como fungicidas.
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112016006366A2 (pt) uso de picolinamidas macrocíclicas como fungicidas
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20150511A (es) Nuevos derivados de purina
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
CO6741154A2 (es) Compuestos de triazolopiridina
CL2018001493A1 (es) Nuevos derivados de fenilo
CR20160448A (es) Nuevos derivados de piridina
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
UY35236A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina